Low SLAMF1 expression was associated with poor survival in CRC and rectum cancer which identified SLAMF1 as a potential biomarker and SLAMF1+ ILCs as a population with anti-tumor effect (64). This evidence concerns the gene SLAMF1 and rectal cancer.